Lilly (Eli)
S&P 500
$1,115.70
-0.65%
Delayed · cached 15 min
Fair value analysis
LLY
Lilly (Eli)
$1,115.70
Close used for this calculation
$452.88Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
53/100
Quality radar
Consensus fair value
$452.88
Above FV▼ -59.4% against the close used
Model range $139.91 – $602.44
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$139.91Fair value$452.88Bull$602.44
FairClose
52-week traded range
52W low $714.5952W high $1,280.34
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Lilly (Eli) closed at $1,115.70, 146.4% above the consensus fair value of $452.88 drawn from 7 valuation models.
Financial DNA score 53/100 — Good. P/E of 48.6x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$455.53
-59.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
$139.91
-87.5%
√(22.5 × EPS × BVPS)
EPS=22.95, BVPS=37.91 · outside Graham range (P/E 48.6, P/B 29.4) — asset-light, treat as a rough floor
P/E Fair Value
$459.00
-58.9%
EPS × 20x (sector P/E)
EPS=22.95, Sector P/E=20x
Peter Lynch (PEG)
$602.44
-46.0%
EPS × Growth% (PEG = 1 is fair)
EPS=22.95, g=26.3%
EV/EBITDA
$515.78
-53.8%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=27.73B
Reverse DCF
$1,115.70
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 19.1% | Historical: 26.3%
Margin of Safety
$263.61
-76.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=351.48, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.